ReviewJournal of neural transmission (Vienna, Austria : 1996)2026
Therapeutic botulinum toxin preparations: an update.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum neurotoxin (BoNT) is approved for a wide range of therapeutic and aesthetic indications. Many other indication are treated off-label. Therapeutic BoNT preparations consist of the 150kDA two-chain neurotoxin, exerting the therapeutic effect, complexing proteins and excipients. In IncobotulinumtoxinA (INCO), the complexing proteins have been removed. More recently, two products have been approved containing the complex-free neurotoxin: DaxibotulinumtoxinA (DAXI) and RelabotulinumtoxinA (RELA). Excipients may include human serum albumin (HSA), polysorbates, NaCl, KCl, lactose, sucrose, amino acids and phosphates. HSA has been replaced by gelatine and in newer products by polysorbates. Typically, BoNT drugs are stabilised by dehydration through lyophilisation or vacuum drying. More recently, ready-to-use liquid preparations have been introduced: AbobotulinumtoxinA as Alluscience
Indexed as
Identifiers
42084637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.